Cargando…
Severe asthma: anti-IgE or anti-IL-5?
Severe asthma is a discrete clinical entity characterised by recurrent exacerbations, reduced quality of life and poor asthma control as ordinary treatment regimens remain inadequate. Difficulty in managing severe asthma derives partly from the multiple existing phenotypes and our inability to recog...
Autores principales: | Papathanassiou, Evgenia, Loukides, Stelios, Bakakos, Petros |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102127/ https://www.ncbi.nlm.nih.gov/pubmed/27834175 http://dx.doi.org/10.3402/ecrj.v3.31813 |
Ejemplares similares
-
Severe Eosinophilic Asthma
por: Bakakos, Agamemnon, et al.
Publicado: (2019) -
Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
por: Bakakos, Agamemnon, et al.
Publicado: (2021) -
Severe Asthma in the Era of Biologics: Continuous Challenges
por: Schoini, Pinelopi, et al.
Publicado: (2023) -
Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma
por: AlShareef, Saad, et al.
Publicado: (2022) -
An algorithmic approach for the treatment of severe uncontrolled asthma
por: Zervas, Eleftherios, et al.
Publicado: (2018)